

Lindsey E Roeker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4218236/publications.pdf>

Version: 2024-02-01

37
papers

1,594
citations

516710

16
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

2355
citing authors

#	ARTICLE	IF	CITATIONS
1	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	13.7	260
2	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
3	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
4	COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 2703-2705.	7.2	126
5	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	27.0	87
6	Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 3047-3049.	7.2	81
7	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
8	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.	6.2	64
9	Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 568-576.	5.0	62
10	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55
11	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	1.4	53
12	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	4.1	52
13	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K γ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	1.4	38
14	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
15	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
16	Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia. <i>JAMA Network Open</i> , 2019, 2, e1916326.	5.9	22
17	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	5.2	22
18	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. <i>Blood Advances</i> , 2021, 5, 2879-2889.	5.2	16

#	ARTICLE	IF	CITATIONS
19	Imatinib-associated melanosis of the palate. American Journal of Hematology, 2014, 89, 564-564.	4.1	14
20	Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 529-539.	2.0	14
21	Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. Blood, 2020, 136, 39-41.	1.4	13
22	Pruritus in primary myelofibrosis: Clinical and laboratory correlates. American Journal of Hematology, 2012, 87, 136-138.	4.1	12
23	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
24	The potential of pirtobrutinib in multiple B-cell malignancies. Therapeutic Advances in Hematology, 2022, 13, 204062072211016.	2.5	12
25	Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e421-e426.	0.4	9
26	Cyclic Bicytopenia in a Patient with Shapiro Syndrome. Case Reports in Hematology, 2013, 2013, 1-4.	0.4	8
27	Approaches for relapsed CLL after chemotherapy-free frontline regimens. Hematology American Society of Hematology Education Program, 2020, 2020, 10-17.	2.5	8
28	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia and Lymphoma, 2021, 62, 1940-1948.	1.3	7
29	Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival. Journal of Geriatric Oncology, 2013, 4, 249-254.	1.0	6
30	Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. Blood, 2012, 120, 3555-3555.	1.4	6
31	Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. Drugs, 2022, 82, 133-143.	10.9	6
32	Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice. British Journal of Haematology, 2021, 194, 9-10.	2.5	3
33	The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 1-5.	2.7	1
34	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. Blood, 2012, 120, 934-934.	1.4	0
35	Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients. Blood, 2013, 122, 3134-3134.	1.4	0
36	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. Blood, 2015, 126, 1401-1401.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). <i>Blood</i> , 2020, 136, 19-22.	1.4	0